Evolus (NASDAQ: EOLS) net income
Evolus reported a net loss of $51.6m for fiscal 2025; in fiscal 2024 it reported a net loss of $50.4m. Earnings per share were −$0.80.
Evolus's best year of the last 9 was fiscal 2017. It reported a loss in 9 of those 9 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | −$51.6m | — | −17.4% | −$0.80 |
| 2024 | −$50.4m | — | −18.9% | −$0.81 |
| 2023 | −$61.7m | — | −30.5% | −$1.08 |
| 2022 | −$74.4m | — | −50.1% | −$1.33 |
| 2021 | −$46.8m | — | −47.0% | −$0.94 |
| 2020 | −$163.0m | — | −288.3% | −$4.83 |
| 2019 | −$90.0m | — | −257.8% | — |
| 2018 | −$46.9m | — | — | — |
| 2017 | −$4.5m | — | — | — |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Evolus net income compared with its sector
By net income for its latest fiscal year, Evolus ranks 259th of the 501 US health care companies with a page on Celsmar. The sector median net margin is −6.2%; that of Evolus, −17.4%.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 257th | Sagimet Biosciences | −$51.0m | — |
| 258th | Establishment Labs | −$51.1m | −24.2% |
| 259th | Evolus | −$51.6m | −17.4% |
| 260th | Invivyd | −$52.5m | −98.2% |
| 261st | Tenax Therapeutics | −$52.6m | — |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Evolus
- How much did Evolus earn in fiscal 2025?
- Evolus reported a net loss of $51.6m for fiscal 2025. In fiscal 2024 it reported a net loss of $50.4m.
- What are the earnings per share of Evolus?
- They were −$0.80 in fiscal 2025, compared with −$0.81 in fiscal 2024.
- Where does Evolus rank in its sector by net income?
- It ranks 259th of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Evolus come from?
- From the annual report (Form 10-K) that Evolus files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Evolus files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017. More on Evolus: the Evolus page · annual accounts · revenue · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.